To overcome pancreatic cancer's immunosuppressive barriers, this study explores a dual approach: triggering immunogenic tumor cell death at the primary tumor site with irinotecan‐loaded silicasomes and enhancing immune activation in the spleen using LNPs encapsulating tumor antigen mRNA and a TLR7/8 agonist. This evidence concerns the gene TLR7 and neoplasm.